Cart
sales@molnova.com
OXF BD 02
CAS No. 1429129-68-9
OXF BD 02( —— )
Catalog No. M33898 CAS No. 1429129-68-9
OXF BD 02 is a potent and selective BRD4(1) inhibitor (IC50: 382 nM) with anticancer and anti-inflammatory activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 235 | In Stock |
|
| 10MG | 353 | In Stock |
|
| 25MG | 655 | In Stock |
|
| 50MG | 917 | In Stock |
|
| 100MG | 1228 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2474 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOXF BD 02
-
NoteResearch use only, not for human use.
-
Brief DescriptionOXF BD 02 is a potent and selective BRD4(1) inhibitor (IC50: 382 nM) with anticancer and anti-inflammatory activity.
-
DescriptionOXF BD 02 is a selective inhibitor of BRD4(1) (the first bromodomain of BRD4) with IC50value of 382 nM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1429129-68-9
-
Formula Weight295.33
-
Molecular FormulaC18H17NO3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC=1C(C2=CC(C(O)C3=CC=CC=C3)=CC(O)=C2)=C(C)ON1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hewings DS, et al. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands. J Med Chem. 2013 Apr 25;56(8):3217-27. ?
molnova catalog
related products
-
Alobresib
Alobresib is an inhibitor of BET bromodomain,is an antineoplastic drug candidate.
-
SMARCA-BD ligand 1 f...
SMARCA-BD ligand 1 for Protac dihydrochloride binds to the BAF ATPase subunit SMARCA2 and is used for degrading SMARCA2 based on PROTAC.
-
GSK778 hydrochloride
GSK778 hydrochloride hydrochloride is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC50s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively.
